scholarly journals Clinical and Epidemiological Differences Among Meningococcal C Conjugate Vaccine Failures and Non-Vaccinated Cases

2016 ◽  
Vol 2 (1) ◽  
pp. 1-9
Author(s):  
Macarena Garrido-Estepa ◽  
2004 ◽  
Vol 9 (7) ◽  
pp. 5-6 ◽  
Author(s):  
R Cano ◽  
A Larrauri ◽  
S Mateo ◽  
B Alcalá ◽  
C Salcedo ◽  
...  

The new meningococcal C conjugate vaccine became available in Spain and was included in the infant vaccination schedule in 2000. A catch-up campaign was carried out in children under six years of age. As a consequence, the incidence of meningococcal disease caused by serogroup C has fallen sharply during the last three epidemiological years in Spain. The risk of contracting serogroup C disease in 2002/2003 fell by 58% when compared with the season before the conjugate vaccine was introduced. There was also an important decrease in mortality. Three deaths due to serogroup C occurred in the age groups targeted for vaccination in 2002/2003, compared with 30 deaths in the same age groups in the season before the launch of the vaccine campaign. In the catch-up campaign the vaccine coverage reached values above 92%. For the 2001, 2002 and 2003 routine childhood immunisation programme coverage values ranged from 90% to 95%. During the past three years a total of 111 cases of serogroup C disease have been reported in patients in the vaccine target group. Most of the vaccination failures occurred during the epidemiological year 2002/2003. Eight (53%) vaccine failures occurred in children who had been routinely immunised in infancy, and could be related to a lost of protection with time since vaccination. The isolation of several B:2a:P1.5 strains (ST-11 lineage) is noteworthy. These may have their origin in C:2a:P1.5 strains which, after undergoing genetic recombination at the capsular operon level, express serogroup B. These strains could have relevant epidemic potential.


The Lancet ◽  
1997 ◽  
Vol 349 (9060) ◽  
pp. 1197-1202 ◽  
Author(s):  
Robert Booy ◽  
Paul T Heath ◽  
Mary PE Slack ◽  
Norman Begg ◽  
E Richard Moxon

2016 ◽  
Vol 35 (4) ◽  
pp. 460-463 ◽  
Author(s):  
Fernando Moraga-Llop ◽  
Juan-Jose Garcia-Garcia ◽  
Alvaro Díaz-Conradi ◽  
Pilar Ciruela ◽  
Johanna Martínez-Osorio ◽  
...  

2010 ◽  
Vol 17 (7) ◽  
pp. 1104-1110 ◽  
Author(s):  
Rachel A. Foster ◽  
Jennifer Carlring ◽  
Andrew Lees ◽  
Ray Borrow ◽  
Mary Ramsay ◽  
...  

ABSTRACT Some individuals have experienced meningococcal disease despite receiving the meningococcal serogroup C conjugate (MCC) vaccine in adolescence. We sought to determine whether this is due to subclinical functional B- or T-cell immunodeficiency. Of 53 vaccine failures identified by enhanced surveillance of England and Wales from 1999 to 2004, 15 received MCC vaccine in adolescence, 9 of whom were recruited 2 to 6 years following convalescence from meningococcal disease. Their peripheral blood mononuclear cells (PBMCs) were incubated with polyclonal activators designed to mimic T-cell-independent B-cell stimulation by bacterial polysaccharides and the T-cell stimulation provided by the protein component of the conjugate vaccine. Subsequent proliferation and activation of T and B lymphocytes were measured, along with T-cell help to B cells. Compared to age-, sex-, geographically, and ethnicity-matched controls, CD4 T-cell proliferation rates in response to both anti-CD3 (T-cell receptor [TCR]) stimulation and anti-CD3 in the presence of B cells activated through anti-IgD conjugated to dextran (α-δ-dex) were lower in PBMCs derived from vaccine failures (P = 0.044 and P = 0.029, respectively). There was reduced CD4 cell activation of the patient cells compared to controls following stimulation by CD3 (P = 0.048). B-cell activation during incubation of PBMCs with the T-cell stimuli, anti-CD3 (P = 0.044), or anti-CD3 plus anti-CD28 (P = 0.018) was relatively impaired in patients. Anti-tetanus toxoid IgG concentrations were lower in the vaccine failure group (P = 0.0385). There was a relative defect of T-cell responsiveness to T-cell-dependent antigen stimulation in MCC vaccine failures, which was manifested in reduced T-cell help to B cells.


Sign in / Sign up

Export Citation Format

Share Document